Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients

References

• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. doi:10.3322/caac.21559
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Rosendahl M, Høgdall CK, Mosgaard BJ. Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer off J Int Gynecol Cancer Soc. 2016;26(4):680–687. doi:10.1097/IGC.0000000000000675
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.118
   PubMed Web of Science ®Google Scholar
• Ataseven B, Du Bois A, Reinthaller A, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;138(3):560–565. doi:10.1016/j.ygyno.2015.07.005
   PubMed Web of Science ®Google Scholar
• Goins EC, Weber JM, Truong T, et al. Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: analysis using a national surgical outcomes database. Gynecol Oncol. 2022;165(2):309–316. doi:10.1016/j.ygyno.2022.01.030
   PubMed Web of Science ®Google Scholar
• Xie H, Ruan G, Wei L, et al. Comprehensive comparison of the prognostic value of systemic inflammation biomarkers for cancer cachexia: a multicenter prospective study. Inflamm Res off J Eur Histamine Res Soc Al. 2022;2022:1. doi:10.1007/s00011-022-01626-7
   Google Scholar
• Li Y, Zhang C, Ji R, et al. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer. Int J Gynecol Cancer off J Int Gynecol Cancer Soc. 2020;30(1):74–82. doi:10.1136/ijgc-2019-000865
   PubMed Web of Science ®Google Scholar
• Yoshikawa N, Yoshida K, Tamauchi S, et al. The preoperative prognostic nutritional index for the prediction of outcomes in patients with early-stage ovarian clear cell carcinoma. Sci Rep. 2020;10(1):7135. doi:10.1038/s41598-020-64171-5
   PubMed Web of Science ®Google Scholar
• Farolfi A, Scarpi E, Greco F, et al. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep. 2020;10(1):18190. doi:10.1038/s41598-020-75316-x
   PubMed Web of Science ®Google Scholar
• Lei H, Xu S, Mao X, et al. Systemic immune-inflammatory index as a predictor of lymph node metastasis in endometrial cancer. J Inflamm Res. 2021;14:7131–7142. doi:10.2147/JIR.S345790
   PubMed Web of Science ®Google Scholar
• Luo Y, Kim HS, Kim M, Lee M, Song YS. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis. J Gynecol Oncol. 2017;28(3):e36. doi:10.3802/jgo.2017.28.e36
   PubMed Web of Science ®Google Scholar
• Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study. Gynecol Oncol. 2019;152(2):259–264. doi:10.1016/j.ygyno.2018.11.034
   PubMed Web of Science ®Google Scholar
• Xiang J, Zhou L, Li X, et al. Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. Transl Oncol. 2017;10(1):33–39. doi:10.1016/j.tranon.2016.10.006
   PubMed Web of Science ®Google Scholar
• Williams KA, Labidi-Galy SI, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132(3):542–550. doi:10.1016/j.ygyno.2014.01.026
   PubMed Web of Science ®Google Scholar
• Iseki Y, Shibutani M, Maeda K, et al. Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS One. 2015;10(7):e0132488. doi:10.1371/journal.pone.0132488
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267(3):527–531. doi:10.1097/SLA.0000000000002115
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Cassatella MA, Östberg NK, Tamassia N, Soehnlein O. Biological roles of neutrophil-derived granule proteins and cytokines. Trends Immunol. 2019;40(7):648–664. doi:10.1016/j.it.2019.05.003
   PubMed Web of Science ®Google Scholar
• Si G, Fr G. Immunity, inflammation, and cancer. Cell. 2010;140:6. doi:10.1016/j.cell.2010.01.025
   Web of Science ®Google Scholar
• Kiss M, Caro AA, Raes G, Laoui D. Systemic reprogramming of monocytes in cancer. Front Oncol. 2020;10:1399. doi:10.3389/fonc.2020.01399
   PubMed Web of Science ®Google Scholar
• Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–970. doi:10.1016/j.ctrv.2015.10.002
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Arch Gynecol Obstet. 2018;297(4):849–857. doi:10.1007/s00404-018-4678-8
   PubMed Web of Science ®Google Scholar
• Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018;150(1):31–37. doi:10.1016/j.ygyno.2018.05.004
   PubMed Web of Science ®Google Scholar
• Miao Y, Yan Q, Li S, Li B, Feng Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark Sect Dis Markers. 2016;17(1):33–40. doi:10.3233/CBM-160614
   PubMed Web of Science ®Google Scholar
• Marchetti C, D’Indinosante M, Bottoni C, et al. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci Rep. 2021;11(1):11125. doi:10.1038/s41598-021-90361-w
   PubMed Web of Science ®Google Scholar
• Sanna E, Tanca L, Cherchi C, et al. Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a predictive and prognostic marker in advanced ovarian cancer. Diagn Basel Switz. 2021;11(7):1298. doi:10.3390/diagnostics11071298
   PubMed Web of Science ®Google Scholar
• Gong J, Jiang H, Shu C, et al. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. J Ovarian Res. 2019;12(1):51. doi:10.1186/s13048-019-0527-z
   PubMedGoogle Scholar
• Tang Y, Hu H, Tang F, et al. Combined preoperative LMR and CA125 for prognostic assessment of ovarian cancer. J Cancer. 2020;11(11):3165–3171. doi:10.7150/jca.42477
   PubMed Web of Science ®Google Scholar
• Eo W, Kim HB, Lee YJ, Suh DS, Kim KH, Kim H. Preoperative lymphocyte-monocyte ratio is a predictor of suboptimal cytoreduction in stage III-IV epithelial ovarian cancer. J Cancer. 2016;7(13):1772–1779. doi:10.7150/jca.15724
   PubMed Web of Science ®Google Scholar
• de Jong D, Eijkemans MJ, Lie Fong S, et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology. 2007;72(5–6):293–301. doi:10.1159/000113051
   PubMed Web of Science ®Google Scholar
• Chen W, Zhong S, Shan B, et al. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications. J Ovarian Res. 2020;13(1):89. doi:10.1186/s13048-020-00693-w
   PubMed Web of Science ®Google Scholar
• Zhang D, Xi Y, Feng Y. Ovarian cancer risk in relation to blood lipid levels and hyperlipidemia: a systematic review and meta-analysis of observational epidemiologic studies. Eur J Cancer Prev off J Eur Cancer Prev Organ ECP. 2021;30(2):161–170. doi:10.1097/CEJ.0000000000000597
   PubMed Web of Science ®Google Scholar
• Onwuka JU, Okekunle AP, Olutola OM, Akpa OM, Feng R. Lipid profile and risk of ovarian tumours: a meta-analysis. BMC Cancer. 2020;20(1):200. doi:10.1186/s12885-020-6679-9
   PubMed Web of Science ®Google Scholar
• Karakaş S, Demirayak G, Önder AB, et al. The association between the preoperative prognostic nutritional index and the controlling nutritional status score on tumor stage, chemotherapeutic response and overall survival in ovarian cancer. Nutr Cancer. 2022;74(5):1770–1779. doi:10.1080/01635581.2021.2022170
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104(5):863–870. doi:10.1038/sj.bjc.6606092
   PubMed Web of Science ®Google Scholar
• Hefler-Frischmuth K, Lafleur J, Hefler L, et al. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors. Gynecol Oncol. 2015;136(3):567–570. doi:10.1016/j.ygyno.2014.12.041
   PubMed Web of Science ®Google Scholar
• Li L, Tian J, Zhang L, et al. Utility of preoperative inflammatory markers to distinguish epithelial ovarian cancer from benign ovarian masses. J Cancer. 2021;12(9):2687–2693. doi:10.7150/jca.51642
   PubMed Web of Science ®Google Scholar
• Yun TH, Jeong YY, Lee SJ, Choi YS, Ryu JM. Neutrophil–lymphocyte and platelet–lymphocyte ratios in preoperative differential diagnosis of benign, borderline, and malignant ovarian tumors. J Clin Med. 2022;11(5):1355. doi:10.3390/jcm11051355
   PubMed Web of Science ®Google Scholar
• Huang K, Xu S, Wang J, Ge L, Xu J, Jia X. Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors. J Ovarian Res. 2023;16:37. doi:10.1186/s13048-023-01106-4
   PubMed Web of Science ®Google Scholar
• Chen S, Wu Y, Wang S, Wu J, Wu X, Zheng Z. A risk model of gene signatures for predicting platinum response and survival in ovarian cancer. J Ovarian Res. 2022;15(1):39. doi:10.1186/s13048-022-00969-3
   PubMed Web of Science ®Google Scholar
• Zheng J, Guo J, Zhu L, Zhou Y, Tong J. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients. J Ovarian Res. 2021;14(1):124. doi:10.1186/s13048-021-00881-2
   PubMed Web of Science ®Google Scholar
• Cardillo N, Devor EJ, Pedra Nobre S, et al. Integrated clinical and genomic models to predict optimal cytoreduction in high-grade serous ovarian cancer. Cancers. 2022;14(14):3554. doi:10.3390/cancers14143554
   PubMed Web of Science ®Google Scholar
• Qian L, Ren J, Liu A, et al. MR imaging of epithelial ovarian cancer: a combined model to predict histologic subtypes. Eur Radiol. 2020;30(11):5815–5825. doi:10.1007/s00330-020-06993-5
   PubMed Web of Science ®Google Scholar
• Yao F, Ding J, Lin F, et al. Nomogram based on ultrasound radiomics score and clinical variables for predicting histologic subtypes of epithelial ovarian cancer. Br J Radiol. 2022;95(1136):20211332. doi:10.1259/bjr.20211332
   PubMed Web of Science ®Google Scholar
• Kumar A, Janco JM, Mariani A, et al. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2016;140(1):15–21. doi:10.1016/j.ygyno.2015.10.025
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64(16):5882–5890. doi:10.1158/0008-5472.CAN-04-0746
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31. doi:10.1016/j.ygyno.2009.03.018
   PubMed Web of Science ®Google Scholar
• Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol off J Am Soc Clin Oncol. 2007;25(24):3621–3627. doi:10.1200/JCO.2006.10.2517
   PubMed Web of Science ®Google Scholar
• Wang Q, Feng X, Liu X, Zhu S. Prognostic value of elevated pre-treatment serum CA-125 in epithelial ovarian cancer: a meta-analysis. Front Oncol. 2022;12:868061. doi:10.3389/fonc.2022.868061
   PubMed Web of Science ®Google Scholar
• Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G. Chemotherapy in epithelial ovarian cancer. Cancer Lett. 2011;303(2):73–83. doi:10.1016/j.canlet.2011.01.026
   PubMed Web of Science ®Google Scholar